GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Valuation Rank

Qrons (QRON) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Qrons Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Qrons Valuation Rank Related Terms

Thank you for viewing the detailed overview of Qrons's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Qrons Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Valuation Rank
Comparable Companies
GRTX NBY ZVSA SCNI AGTX MTNB WINT ACUT SXTP GNPX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
28-10 Jackson Avenue, No. 26N, Long Island, NY, USA, 11101
Website
https://www.qrons.com
Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.
Executives
John N Bonfiglio officer: Chief Operating Officer C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer director, 10 percent owner, officer: CEO, CFO and Secretary 28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld director, 10 percent owner, officer: President 153 HAGILBOA STREET, NIRIT L3 44805